Drug-Target Interaction

Drug

PubChem ID:

Structure:

Synonyms:

(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-amino-3-(4-sulfooxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid

25613-79-0

8-Nle-cer(4-10)

8-Norleucine-ceruletide(4-10)

AC1L51SA

Caerulein(4-10), nle(8)-

Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-3-de-L-aspartic

Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-3-de-L-aspartic acid-8-L-norleucine-

Ceruletide

Ceruletide(4-10), 8-norleucine-

CID168399

DB00403

Nle(8)-ceruletide(4-10)

enlarge table

ATC-Codes:

V04CC04

enlarge table

Target

show target details

Uniprot ID:

Q6P9U7_RAT

Synonyms:

L-lactate dehydrogenase

enlarge table

EC-Numbers:

1.1.1.27

Organism:

Rat
Rattus norvegicus

PDB IDs:

Binding Affinities:

Ki:	Kd:	Ic 50:	Ec50/Ic50:
-	-	-	-

References:

1717033
Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein.. T Hirano; T Manabe; T Tobe (1991) Journal of gastroenterology and hepatology display abstract

Earlier studies have reported that interstitial oedematous pancreatitis characterized by hyperamylasaemia can be seen during the early stage of stimulation of supramaximal dose of caerulein. The present study investigated the changes in both cellular and lysosomal fragility and the protective effects of a synthetic protease inhibitor gabexate mesilate (FOY) on this non-invasive model of experimental pancreatitis. The infusion of FOY (50 mg/kg/h) prevented the caerulein-induced increase in serum amylase and pancreatic oedema formation and reduced the elevated amylase content significantly. The administration of FOY with caerulein also reduced the increased lactic dehydrogenase (LDH) discharge significantly and inhibited the cathepsin B leakage from lysosomes in an in vitro incubation system. These results indicate that FOY plays its protective role at the subcellular level--that is, in lysosomes by inhibiting some proteases such as phospholipase A2. The importance of esterases in the pathogenesis of acute pancreatitis is demonstrated. This type of esterase inhibitor may be valuable clinically in the treatment of acute pancreatitis and these results also suggest the role of lysosomal fragility in the pathogenesis of progression of acute pancreatitis.